Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

200.81 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Apr 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	80,354
Open	200.81
Bid (Size)	206.71 (200)
Ask (Size)	206.83 (100)
Prev. Close	200.81
Today's Range	200.81 - 200.81
52wk Range	182.39 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.46%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Performance

YTD	+6.6%	+6.6%
1 Month	+3.0%	+3.0%
3 Month	+6.6%	+6.6%
6 Month	+6.6%	+6.6%
1 Year	+6.6%	+6.6%

More News

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

April 02, 2026

From AstraZeneca

Via Business Wire

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

Via MarketMinute

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

Via Finterra

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

Via MarketMinute

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

March 27, 2026

From AstraZeneca

Via Business Wire

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

Via Finterra

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

Via MarketMinute

Could This International ETF Be One of the Best Investments of 2026? ↗

March 14, 2026

Via The Motley Fool

The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis

March 13, 2026

Via MarketMinute

The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026

March 11, 2026

Via MarketMinute

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

Via Finterra

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

March 10, 2026

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

March 09, 2026

From AstraZeneca

Via Business Wire

The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026

March 05, 2026

Via MarketMinute

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Via The Motley Fool

As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗

March 02, 2026

Via MarketBeat

After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗

February 27, 2026

Via MarketBeat

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange

February 26, 2026

Via MarketMinute

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

February 20, 2026

From AstraZeneca

Via Business Wire

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Via MarketMinute

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

February 16, 2026

Via The Motley Fool

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 200.81

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 04/07/26 07:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.